ALLMedicine™ Medullary Thyroid Carcinoma Center

Mar 25th, 2023 - Modified to no abstract as requested.

Mar 22nd, 2023 - The pathology of neoplasia tends to focus on the tumor that requires characterization, grading, and staging. However, nontumorous tissue surrounding the lesion can also provide information, particularly about pathogenetic mechanisms. In endocrine ...

Mar 18th, 2023 - Nested is defined as "cellular clusters arranged in small groupings with intervening vascular or stromal networks, lacking lumens or glandular formation." Using this definition, multiple neoplastic and non-neoplastic lesions of the head and neck c...

Mar 17th, 2023 - Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that can be sporadic or inherited and is often associated with mutations in the RET (Rearranged during Transfection) oncogene. The primary treatment for MTC is surgical resection of all...

Mar 17th, 2023 - Background: Medullary Thyroid Carcinoma (MTC) is a calcitonin producing tumor arising from the parafollicular C cells of thyroid. In children and adults, MTC is usually seen in association with Multiple Endocrine Neoplasia (MEN) 2A and 2B, which a...

Mar 27th, 2015 - The American Thyroid Association appointed a Task Force of experts to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the American Thyroid Association. The Task Force identified relevant articles using a systematic PubMed...

Mar 17th, 2023 - Background: Medullary Thyroid Carcinoma (MTC) is a calcitonin producing tumor arising from the parafollicular C cells of thyroid. In children and adults, MTC is usually seen in association with Multiple Endocrine Neoplasia (MEN) 2A and 2B, which a...

Feb 23rd, 2023 - Non-medullary thyroid carcinoma has a good prognosis in most patients. However, a small subset of patients nevertheless develop metastatic or locally advanced and unresectable disease which in some cases also becomes radioiodine refractory. In the...

Nov 29th, 2022 - PRIMARY OBJECTIVES: I. To assess objective response rate of sorafenib tosylate (sorafenib [BAY 43-9006]) in metastatic medullary thyroid carcinoma in setting of inherited tumor syndromes, such as multiple endocrine neoplasia (MEN) 2A, MEN 2B, or f...

Oct 12th, 2022 - An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic ...

Oct 6th, 2022 - This active surveillance program will monitor for any signal indicating a possible association between treatment with long-acting GLP-1 RAs and the development of MTC in the United States population. Given the very low incidence of MTC in the gene...

May 5th, 2022 - Investigators at the Perelman School of Medicine at the University of Pennsylvania (Penn) have recently initiated a clinical trial evaluating a novel CAR T-cell therapy in an effort to fill an unmet need for systemic treatment for patients with ad...

Apr 8th, 2022 - A new consensus statement from the American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group focuses on a definition of advanced thyroid cancer and outlines strategies for mutation testing and targeted treat.

Oct 6th, 2021 - Julie Ann Sosa, MD, MA, FACS, FSSO, chair, Department of Surgery, Leon Goldman, MD Distinguished Professor of Surgery, professor, Department of Medicine, affiliated faculty, Philip R. Lee Institute for Health Policy Studies, University of Californ...

Oct 6th, 2021 - The RET inhibitor TPX-0046 demonstrated encouraging preliminary activity, which included objective responses, and an acceptable toxicity profile when used in patients with RET-driven advanced solid tumors, according to data from the phase 1/2 SWOR...

Jun 21st, 2021 - This transcript has been edited for clarity. Hi. Today we're going to talk about another form of semaglutide. This form is called Wegovy, and it's indicated for weight loss in people with or without diabetes. It's a higher dose than we've used bef...